SEMLER SCIENTIFIC ($NASDAQ:SMLR) reported their second quarter FY2023 earnings results on June 30 2023, with the quarter ending on August 10 2023. Their total revenue for the period increased by 25.4% from the same time last year, totaling USD 18.6 million. Furthermore, their net income rose 44.5% to USD 5.9 million.
After the results were released, the stock opened at $23.7 and closed at $23.5, representing a 0.8% decrease from the previous closing price of $23.7. These earnings results showed mixed results, with some areas of improvement, while other areas remain uncertain. This was mainly attributed to the increase in research and development and marketing expenses during this period, as well as an increase in taxes paid. Looking ahead, SEMLER SCIENTIFIC will continue to focus on increasing its market share in the medical sector and expanding its global presence.
The company is also aiming to grow its revenues through new product launches and strategic partnerships with other companies. Overall, SEMLER SCIENTIFIC remains confident in its ability to deliver strong returns to its shareholders in the future. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Semler Scientific. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Semler Scientific. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Semler Scientific. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Semler Scientific are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
GoodWhale has conducted an analysis of SEMLER SCIENTIFIC‘s financials with our GoodWhale software. According to our Star Chart, SEMLER SCIENTIFIC has an outstanding health score of 10/10, meaning they have a strong capacity to pay off debt and fund future operations. We have classified SEMLER SCIENTIFIC as a ‘gorilla’, a type of company that has achieved stable and high revenue or earning growth due to its strong competitive advantage. Given SEMLER SCIENTIFIC’s strong asset, growth, and profitability scores, this company may be of interest to venture capitalists, private equity firms, and growth-oriented mutual funds. However, due to their weak dividend score, this company may not be of interest to dividend investors. More…
Risk Rating Analysis
Star Chart Analysis
The Company operates through two segments: Semler and Quidel. Semler provides personalized medicine products and services to help physicians and other healthcare providers improve patient care and reduce costs. Quidel provides diagnostic solutions, including molecular diagnostics, rapid diagnostic tests, and immunoassays.
– Rapid Micro Biosystems Inc ($NASDAQ:RPID)
The company’s market cap is $104.86 million and its ROE is -20.93%. The company develops and manufactures rapid microbiological testing products for use in the pharmaceutical, biotechnology, food, and cosmetics industries. Its products include the Growth Direct System, a rapid automated microorganism detection and enumeration system; the AquaSnap Total aerobic Count Test, a water testing system; and the Compendial Counts Test, a method for enumerating aerobic microorganisms in food and cosmetics.
– Applied BioCode Corp ($TWSE:6598)
Applied BioCode, Inc. is a molecular diagnostics company, which focuses on the development and commercialization of multiplex molecular solutions that simplify and improve the diagnosis of infectious diseases and cancer. Its products include BioCode MDx, a multiplex molecular diagnostic platform that can be used for the simultaneous detection and identification of multiple pathogens from a single patient specimen; and Respiratory Pathogen Panel, a multiplexed molecular diagnostic test that detects and identifies common viral and bacterial respiratory pathogens. The company was founded by David J. Wilson, Bruce A. Weintraub, and Gerald V. Niedzwiecki in 2000 and is headquartered in Carlsbad, CA.
As of 2022, Sinocare Inc has a market cap of 20.82B and a Return on Equity of 7.01%. The company is a leading provider of diabetes management products and services in China.
SEMLER SCIENTIFIC reported strong earnings results for the second quarter of FY2023, with total revenue increasing by 25.4% and net income up 44.5%. These strong figures represent a great investment opportunity for investors, as they demonstrate the company’s resilient financial performance in a challenging economic climate. Additionally, the numbers display SEMLER SCIENTIFIC’s commitment to delivering sustainable and profitable growth to its shareholders. Investors should consider this stock as an attractive option, with its strong financial position and promising future outlook.